---
id: "framework-amc-innovation-acceleration"
type: "framework"
source_timestamps: ["§ How to Accelerate Innovation"]
tags: ["strategy", "institutional-reform", "innovation-management"]
related: ["concept-in-house-accelerators", "concept-self-driving-labs", "concept-amc-strategic-financing", "concept-amc-innovators-dilemma", "action-portfolio-management", "action-integrate-sdls", "action-establish-ai-governance", "action-strategic-vc-partnerships", "action-cross-border-trials"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# 5-Pillar Model for Accelerating AMC Innovation

The authors propose a **five-part strategic framework** for U.S. academic medical centers to overcome their [[concept-amc-innovators-dilemma]] and compete globally. It requires moving beyond traditional basic-science and technology-transfer models into **integrated, highly capitalized, and technologically advanced** operational models. Notably, **to date no single U.S. AMC has fully implemented all five elements** — the examples below are best-in-class fragments, not a finished template.

**Pillar 1 — Embrace a new model for accelerating drug development.** Build in-house accelerators ([[concept-in-house-accelerators]]) with **industry-style portfolio management** that prioritizes first-in-class candidates. → Action: [[action-portfolio-management]] · Example: [[entity-stanford-ima]].

**Pillar 2 — Integrate emerging technologies into the drug-development process.** Deploy **AI + robotic automation / Self-Driving Labs** ([[concept-self-driving-labs]]) to replace manual workflows. → Action: [[action-integrate-sdls]] · Examples: [[entity-purdue-care]], [[entity-mount-sinai-ai]].

**Pillar 3 — Use strategic partnerships to unlock the value of AI** without building everything in-house, backed by **thoughtful governance frameworks**. → Action: [[action-establish-ai-governance]] · Examples: [[entity-msk]], [[entity-aws-ddw]], [[entity-triomics]] · Open question: [[question-ai-ip-governance]].

**Pillar 4 — Extend research investments beyond early-stage science** via strategic financing and VC partnerships ([[concept-amc-strategic-financing]]). → Action: [[action-strategic-vc-partnerships]] · Example: [[entity-cleveland-clinic-d2]] + [[entity-khosla-ventures]].

**Pillar 5 — Continue to drive global collaborations** to optimize clinical-trial design, patient enrollment, and regulatory harmonization. → Action: [[action-cross-border-trials]] · Example: [[entity-msk]] (U.S.–Australia Alliance) · Rationale: [[quote-disease-borders]].

**Steps (verbatim intent):**
1. Embrace a new model for accelerating drug development (in-house accelerators with industry-style portfolio management).
2. Integrate emerging technologies (AI and robotic automation / Self-Driving Labs) to replace manual workflows.
3. Use strategic partnerships to unlock AI value without building everything in-house, backed by thoughtful governance frameworks.
4. Extend research investments beyond early-stage science via strategic financing and venture-capital partnerships.
5. Continue to drive global collaborations to optimize clinical-trial design, patient enrollment, and regulatory harmonization.